Imatinib blocks the binding of ATP to the BCR-ABL tyrosine kinase[22,23], and is currently used as the first-line treatment for CML[2,4]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.